peptide vaccine Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (1)
Phase 2 (1)

Interventional (2)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

No (2)

No (2)

Adult (18+) (2)
Pediatric (Under 18) (1)

I am/have/had

I am/have/hadcancer

I am/have/hadmeasurable disease

I am/have/hadplatelet count

I am/have/hadsecond malignancy

I am/have/hadsquamous cell carcinoma of the head and neck

I am/have/hadcarcinoma

I am/have/hadcarcinoma in situ of cervix

I am/have/hadcore needle biopsy

I am/have/hadhead and neck carcinoma

I am/have/hadmetastasis

I am/have/hadneutrophil count

I am/have/hadhepatocellular carcinoma

I am/have/hadsquamous cell carcinoma

I am/have/hadskin cancer

I am/have/hadcavity

I am/have/hadcarcinoma in situ of the cervix

added new label for I am/have/had

more

I am looking for

I am looking forpeptide vaccine

I am looking forio102

I am looking foripilimumab

I am looking fornivolumab

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For pediatric ages
For Seniors
Recruiting in 10s
Interventional Study
all
Recruiting

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and to assess the T-cell response.

measurable disease

nivolumab

peptide vaccine

cancer

carcinoma

0 views
19 Feb, 2024

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

second malignancy

metastasis

squamous cell carcinoma of the head and neck

measurable disease

platelet count

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.